ADMA Biologics Inc (ADMA)
Return on assets (ROA)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 197,673 | -28,239 | -65,904 | -71,648 | -75,749 |
| Total assets | US$ in thousands | 488,678 | 329,182 | 348,461 | 276,253 | 207,673 |
| ROA | 40.45% | -8.58% | -18.91% | -25.94% | -36.48% |
December 31, 2024 calculation
ROA = Net income ÷ Total assets
= $197,673K ÷ $488,678K
= 40.45%
ADMA Biologics Inc's return on assets (ROA) has shown a significant improvement over the years. The ROA was -36.48% as of December 31, 2020, indicating that the company was generating a negative return on its assets. This negative trend continued in 2021 and 2022, with ROA figures of -25.94% and -18.91%, respectively.
However, there was a notable turnaround in 2023, with the ROA improving to -8.58%. This improvement suggests that the company was becoming more efficient in generating profits from its assets. By December 31, 2024, ADMA Biologics Inc's ROA surged to a positive 40.45%, indicating that the company was able to generate a significant return on its assets, potentially due to improved operational efficiency or better utilization of resources.
Overall, the improving trend in ROA from 2020 to 2024 demonstrates that ADMA Biologics Inc is making strides in optimizing its asset utilization and profitability, which could be a positive sign for investors and stakeholders.
Peer comparison
Dec 31, 2024